Buying in as a contrarian play is taking on the risks that Nextstellis is a dud, that dermatology and Contract Services are also duds and that generic margins continue to be squeezed and that Nuvaring never gets approved or too late to have a meaningful impact on sales.
That is a lot of risk.
I am making the same assessment as to whether to sell and take a 60% loss from my initial investment back in Nov'16. The opportunity loss alone is huge.
I believe Nexstellis will be a good investment.
I believe that MYX has developed a solid dermatology business.
I believe that Contract Services is a very good business and is a sleeper.
I could not care less about Nuvaring, it's not there now so why bother being 4th to market.
Ah generics. What a crock. I wish they would sell it.
So my dilemma is: Can Nexstellis+Dermatology+Contract Services overcome the demise in generics with Scott Richards at the helm?
For me the jury is out, but the clock is now ticking very loudly.
- Forums
- ASX - By Stock
- Ann: 2021 Full Year Investor Presentation
Buying in as a contrarian play is taking on the risks that...
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.56 |
Change
-0.050(1.08%) |
Mkt cap ! $392.1M |
Open | High | Low | Value | Volume |
$4.59 | $4.59 | $4.56 | $10.97K | 2.393K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 636 | $4.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.57 | 126 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 636 | 4.550 |
5 | 883 | 4.540 |
4 | 4235 | 4.530 |
5 | 1781 | 4.520 |
4 | 625 | 4.510 |
Price($) | Vol. | No. |
---|---|---|
4.570 | 126 | 5 |
4.580 | 600 | 3 |
4.590 | 483 | 2 |
4.600 | 2824 | 4 |
4.610 | 1567 | 3 |
Last trade - 10.25am 04/10/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |